Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Forsteo ® (teriparatide)
Forsteo® (teriparatide): Pharmacokinetic Properties
Teriparatide is quickly absorbed from the injection site, has a half-life of approximately 1 hour, and is undetectable in the blood within 3 hours.
Absorption and Distribution
The half-life of Forsteo is approximately 1 hour when administered subcutaneously, which reflects the time required for absorption from the injection site. 1
The volume of distribution is approximately 1.7 L/kg.1
Biotransformation and Elimination
No metabolism or excretion studies have been performed with Forsteo but the peripheral metabolism of parathyroid hormone is believed to occur predominantly in liver and kidney.1
Forsteo is eliminated through hepatic and extra-hepatic clearance (approximately 62 L/hr in women and 94 L/hr in men).1
Teriparatide is rapidly eliminated with a decrease to nonquantifiable concentrations within 3 hours of the dose.3
2. Satterwhite J, Heathman M, Miller PD, et al. Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcif Tissue Int. 2010;87(6):485-492. http://dx.doi.org/10.1007/s00223-010-9424-6
3. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: November 11, 2019